Blood Feud by Kathleen Sharp
The Man Who Blew the Whistle on One of the Deadliest Prescription Drugs Ever

No critic rating

Waiting for minimum critic reviews

See 5 Critic Reviews



Blood Feud rivals A Civil Action for best non-fiction book of the past twenty years.” — John Lescroart, New York Times bestselling author of Damage

Procrit seemed like a biotech miracle, promising a golden age in medical care. Developed in the 1980s by Amgen and licensed to the pharmaceutical giant, Johnson & Johnson, the drug (AKA Epogen and Aranesp) soon generated billions in annual revenue—and still does.  In 2012, world famous cyclist, Olympian, and Tour de France champion Lance Armstrong was banned from professional cycling on doping charges for using EPO (the blanket name for the drugs Procrit and Epogen), resulting in a global controversy about abuse, big pharmaceutical companies, and the lies and inaccuracies concerning performance-enhancing drugs.

Mark Duxbury was a J&J salesman who once believed in the blood-booster, setting record sales and winning company awards. Then Duxbury started to learn unsavory truths about Procrit and J&J’s business practices. He was fired and filed a whistleblower suit to warn the public.

When Jan Schlichtman (A Civil Action) learned of Duxbury’s crusade, he signed on. Now, he’s fighting on behalf of cancer patients and for every American who trusts Big Pharma with his life.


About Kathleen Sharp

See more books from this Author
Kathleen Sharp is a journalist whose work has appeared in The New York Times Magazine, Parade, Elle, and Fortune, among many other publications; she has won six awards from the Society of Professional Journalists, among other honors. She lives in Santa Barbara, California.
Published August 28, 2012 by Plume. 449 pages
Genres: Business & Economics, Young Adult, Professional & Technical, Law & Philosophy, Health, Fitness & Dieting. Non-fiction

Unrated Critic Reviews for Blood Feud

Kirkus Reviews

See more reviews from this publication

Although the original license specified the drug's use for patients suffering kidney failure, J&J encouraged its use for cancer patients in therapy and started a marketing campaign to encourage doctors to raise the prescribed dosage.

| Read Full Review of Blood Feud: The Man Who Blew ...

Kirkus Reviews

See more reviews from this publication

A committee in Congress started to investigate how Johnson & Johnson and Amgen [the company that discovered epotein alfa, the generic version of Procrit] were promoting these drugs, which one Congressman said might have even been illegal.

Sep 21 2011 | Read Full Review of Blood Feud: The Man Who Blew ...

New York Journal of Books

See more reviews from this publication

When Ortho first introduces the drug in 1991, its sales reps—including Duxbury and McClellan—follow company policy and actively promote the drug;

Sep 20 2011 | Read Full Review of Blood Feud: The Man Who Blew ...

Bookmarks Magazine

Developed by Amgen and licensed to a Johnson & Johnson company, the drug was sold by the two companies under the brand names Procrit, Epogen, and Arenesp.The Underdog: Mark Duxbury, Drug Salesman
Duxbury was the gung-ho salesman for the new biotech division of J&J, an irrepres...

Sep 25 2011 | Read Full Review of Blood Feud: The Man Who Blew ...

The Saturday Evening Post

Mark Duxbury was a drug salesman for Johnson & Johnson company Ortho, tasked with selling the performance-enhancing drug Procrit as an alternative to blood transfusions.

Jan 05 2012 | Read Full Review of Blood Feud: The Man Who Blew ...

Reader Rating for Blood Feud

An aggregated and normalized score based on 39 user ratings from iDreamBooks & iTunes

Rate this book!

Add Review